Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Soft Tissue Sarcoma (Sep 2019)

Posted by Matt Breese on Sep 27, 2019

Find me on:

According to our recent payer coverage analysis for soft tissue sarcoma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for soft tissue sarcoma treatments shows that under the pharmacy benefit, about 60% and 70% of the lives under commercial and Medicare formularies are covered with utilization management restrictions, respectively.

MMIT-Reality Check-Soft Tissue Sarcoma_3Q2019Data snapshot as of Q3 2019

Trends: In April 2019, Eli Lilly and Co. said it will withdraw advanced soft tissue sarcoma drug Lartruvo (olaratumab) from the market. The move follows the failure of a Phase III trial in which the therapy did not improve patient survival .   

To read the full Reality Check on Soft Tissue Sarcoma treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing